Pakistan Business News API

{
    "totalArticles": 333128,
    "articles": [
        {
            "id": "38eb6dd9fd6406b20fc5671cc636a355",
            "title": "5 things to know before the market opens Monday",
            "description": "Here are five key things investors need to know to start the trading day.",
            "content": "This is CNBC's Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.\nGood morning. Several pharmaceutical stocks are climbing this morning amid the recent hantavirus outbreak. Officials say the public health risk from th... [4748 chars]",
            "url": "https://www.cnbc.com/2026/05/11/5-things-to-know-before-the-market-opens.html",
            "image": "https://image.cnbcfm.com/api/v1/image/108304409-1778258761124-gettyimages-2274562369-AFP_B2AZ2HY.jpeg?v=1778258839&w=1920&h=1080",
            "publishedAt": "2026-05-11T12:11:57Z",
            "lang": "en",
            "source": {
                "id": "32c2ad3fb41cb87b5b847d750028dff0",
                "name": "CNBC",
                "url": "https://www.cnbc.com"
            }
        },
        {
            "id": "9ef7e4229f3fb46ee69e33dba2a5c9c8",
            "title": "Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates",
            "description": "The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.",
            "content": "Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027\nRecently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z... [13297 chars]",
            "url": "https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-quarter-2026-financial",
            "image": "https://ir.intelliatx.com/sites/g/files/knoqqb88161/files/favicon_0.png",
            "publishedAt": "2026-05-11T11:34:36Z",
            "lang": "en",
            "source": {
                "id": "fff2abdff49d77020a98943703e17e63",
                "name": "Intellia Therapeutics",
                "url": "https://ir.intelliatx.com"
            }
        },
        {
            "id": "aad5874d587fbe2240092c34b6df906d",
            "title": "Kuehne+Nagel and Hapag-Lloyd take their first joint step towards sustainable ocean shipping",
            "description": "First collaboration between Hapag-Lloyd and Kuehne+Nagel on sustainable ocean freight using Sustainable Marine Fuels (SMF)Approx. 3,000 tonnes CO₂e emission reductions agreed as pilot volume for 2026Around 1,000 tonnes of RED III compliant, waste based SMF utilized",
            "content": "Kuehne+Nagel and Hapag-Lloyd are further strengthening their long-standing partnership and, for the first time, collaborating on emission-reduced ocean transport solutions. As part of this agreement, Kuehne+Nagel will utilize Hapag-Lloyd’s “Ship Gree... [2295 chars]",
            "url": "https://newsroom.kuehne-nagel.com/kuehnenagel-and-hapag-lloyd-take-their-first-joint-step-towards-sustainable-ocean-shipping/",
            "image": "https://content.presspage.com/uploads/1918/1920_kn3.jpg?40841",
            "publishedAt": "2026-05-11T10:39:59Z",
            "lang": "en",
            "source": {
                "id": "0b2e7debd94a27210a8a18edca617c6f",
                "name": "Kuehne+Nagel",
                "url": "https://newsroom.kuehne-nagel.com"
            }
        }
    ]
}